Revvity announces development of T-SPOT A201 automated platform
The platform is designed for high-volume latent tuberculosis IGRA testing in clinical labs, improving workflow efficiency and scalability.
See the latest news and media coverage for Revvity. We track all announcements, press releases, and industry mentions in real time, all in one place.
Health science technologies and services company
revvity.comLast updated
In short: Revvity exceeded 2026 Q1 and 2025 Q4 earnings expectations, announced a China unit divestiture, and expanded its AI and R&D software.
The platform is designed for high-volume latent tuberculosis IGRA testing in clinical labs, improving workflow efficiency and scalability.
The announcement followed a visit to Revvity's Turku site and strategic dialogues with Kenyan and Finnish officials.
The framework uses natural language and LLMs within the Signals One platform to help scientists search, understand, and act on complex data while ensuring traceability and scientific rigor.
The cloud-native solution streamlines biologics research workflows and enhances R&D collaboration.
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely...
Revvity stock reflects a business that grew revenue in the low single digits and expanded adjusted operating margin in Q1 2026, while management reiterated its...
Signals Software platform has joined Anthropic's Model Context Protocol directory. The move connects Signals AI to Anthropic's Claude models, aiming to streamline scientific data access...
On October 03, 2023, Wolfe Research has officially assumed coverage of Revvity (RVTY) with a rating...
Track Revvity and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Revvity and other trending companies.